¼¼°èÀÇ ´Ü¹éÁúüÇÐ ½ÃÀå
Proteomics
»óǰÄÚµå : 1760920
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 577 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,124,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,373,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

´Ü¹éÁúüÇÐ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 667¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 374¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ´Ü¹éÁúüÇÐ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 10.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 667¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½Ã¾àÀº CAGR 10.0%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 492¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 11.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 138¾ï ´Þ·¯, Áß±¹Àº CAGR 12.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´Ü¹éÁúüÇÐ ½ÃÀåÀº 2024³â¿¡ 138¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 65¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.8%·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 9.0%¿Í 9.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.7%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ´Ü¹éÁúüÇÐ ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

´Ü¹éÁúüÇÐÀº ´Ü¹éÁú, ±× ±¸Á¶, ±â´É ¹× »ý¹°ÇÐÀû ½Ã½ºÅÛ ³»¿¡¼­ÀÇ »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ ´ë±Ô¸ð ¿¬±¸ÀÔ´Ï´Ù. ´Ü¹éÁúÀº °ÅÀÇ ¸ðµç ¼¼Æ÷ °úÁ¤¿¡ ÇʼöÀûÀ̱⠶§¹®¿¡ ´Ü¹éÁúüÇÐÀº ¼¼Æ÷°¡ ¾î¶»°Ô ±â´ÉÇϰí Áúº´ÀÌ ¾î¶»°Ô ¹ßº´ÇÏ´ÂÁö¿¡ ´ëÇÑ Áß¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ´Ü¹éÁúüÇп¡ »ç¿ëµÇ´Â ±â¼ú¿¡´Â Áú·® ºÐ¼®, ´Ü¹éÁú ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, ´Ü¹éÁú ½Äº° ¹× Á¤·®È­, ´Ü¹éÁú º¯Çü ºÐ¼®, ´Ü¹éÁú °£ »óÈ£ÀÛ¿ëÀ» ¸ÅÇÎÇÏ´Â ´Ù¾çÇÑ »ý¹°Á¤º¸ÇÐ µµ±¸°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ °úÇÐÀÚµéÀº ÇÁ·ÎÅ׿È(»ý¹°, Á¶Á÷, ¼¼Æ÷¿¡¼­ »ý»êµÇ´Â Àüü ´Ü¹éÁú)À» Ž»öÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼­·Î ´Ù¸¥ Á¶°Ç¿¡¼­ ÇÁ·ÎÅ׿ÈÀ» ºñ±³ÇÔÀ¸·Î½á ¿¬±¸ÀÚµéÀº Áúº´ÀÇ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°Çϰí, Áúº´ÀÇ ¸ÞÄ¿´ÏÁòÀ» ÀÌÇØÇϸç, Ç¥Àû Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÃÖ±Ù ´Ü¹éÁúüÇÐÀÇ ¹ßÀüÀº ±× ´É·Â°ú ÀÀ¿ëÀ» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. °íÇØ»óµµ Áú·® ºÐ¼®°ú ÷´Ü »ý¹°Á¤º¸ÇÐ µµ±¸´Â ´Ü¹éÁú ½Äº° ¹× Á¤·®È­ÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì ¹× CRISPR ±â¼ú°ú °°Àº Çõ½ÅÀº ´Ü¹éÁúüÇÐ¿Í À¯ÀüüÇÐ ¹× Àü»çüÇаúÀÇ ÅëÇÕÀ» ÃËÁøÇÏ¿© ¼¼Æ÷ °úÁ¤¿¡ ´ëÇÑ º¸´Ù Á¾ÇÕÀûÀÎ ÀÌÇØ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ´ÜÀÏ ¼¼Æ÷ ´Ü¹éÁúüÇÐÀÇ °³¹ßÀº ¼¼Æ÷ÀÇ ºÒ±ÕÀϼº°ú Áúº´ ÁøÇàÀ» Àü·Ê ¾ø´Â ÇØ»óµµ·Î ¿¬±¸ÇÒ ¼ö ÀÖ´Â »õ·Î¿î ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ¹ßÀüÀº ÇÁ·ÎÅ׿ȿ¡ ´ëÇÑ º¸´Ù Á¤¹ÐÇÏ°í »ó¼¼ÇÑ ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ½Å¾à°³¹ß, ¸ÂÃãÀÇ·á, ÀÓ»óÁø´Ü µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ´Ü¹éÁúüÇÐÀÇ È°¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

´Ü¹éÁúüÇÐ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾Ï, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ °í±Þ Áø´Ü ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ´Ü¹éÁúüÇÐ µµÀÔ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³Àκ° ´Ü¹éÁúüÇÐ ÇÁ·ÎÆÄÀÏÀ» ÀÌÇØÇÏ¿© Ä¡·á¸¦ Á¶Á¤ÇÏ´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á·ÎÀÇ Àüȯµµ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¼ºÀåÀÇ ¿øµ¿·ÂÀ¸·Î´Â ¸¹Àº ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ ´Ü¹éÁú Ç¥ÀûÄ¡·áÁ¦ ¹× Á¤¹Ð ºÐÀÚ ÀǾàǰ °³¹ß, Áú·®ºÐ¼® ±â¹Ý ´Ü¹éÁúüÇÐ °³¹ß, ¾Ç¼º Á¾¾çÀÇ ºÐÀÚ Ç¥Àû °³¹ß µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î ´Ü¹éÁúüÇÐ ÀÀ¿ë ºÐ¾ß ¹ß±¼, ½Å¾à °³¹ß, ½ÉÇ÷°ü Áúȯ ¹× ¾Ï°ú °°Àº ´Ù¾çÇÑ À¯ÇüÀÇ Áúº´¿¡¼­ ´Ü¹éÁúüÇÐ ¹ÙÀÌ¿À¸¶Ä¿ Ž»öÀ» À§ÇÑ ¿¬±¸°³¹ß¿¡ ´ëÇÑ »ý¸í°øÇÐ ±â¾÷ ¹× Á¦¾à ±â¾÷ÀÇ °ü½É Áõ°¡´Â ¼¼°è ´Ü¹éÁúüÇРȯ°æÀÇ ÁÖ¿ä Æ®·»µåÀÔ´Ï´Ù. Áú·® ºÐ¼®°ú ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ÇÁ·ÎÅ×¿È ºÐ¼®ÀÇ ±â´ÉÀÌ °­È­µÇ¾î º¸´Ù ½±°í ºñ¿ë È¿À²ÀûÀ¸·Î ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À¸¶Ä¿ ¹ß±¼ ¹× ÀǾàǰ °³¹ß µîÀÇ ºÐ¾ß¿¡¼­ÀÇ ¿¬±¸ È®´ë°¡ ½ÃÀå °³Ã´¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ¹× ¹Î°£ ±â¾÷ÀÇ ¿¬±¸ ¹× ÀÎÇÁ¶ó ÅõÀÚ, Çаè¿Í Á¦¾à»çÀÇ Çù·Âµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀο¡ ´õÇØ, ´Ü¹éÁúüÇа¡ »ý¸í°úÇÐ ¿¬±¸ÀÇ Áß¿äÇÑ µµ±¸·Î Àνĵǰí ÀÖ´Â °Íµµ ´Ü¹éÁúüÇÐ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÄÄÆ÷³ÍÆ®(½Ã¾à, ±â±â, ¼­ºñ½º);¿ëµµ(Drug Discovery, Áúº´ Áø´Ü, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 178°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Proteomics Market to Reach US$66.7 Billion by 2030

The global market for Proteomics estimated at US$37.4 Billion in the year 2024, is expected to reach US$66.7 Billion by 2030, growing at a CAGR of 10.1% over the analysis period 2024-2030. Reagents, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$49.2 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 11.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.8 Billion While China is Forecast to Grow at 12.8% CAGR

The Proteomics market in the U.S. is estimated at US$13.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 12.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.0% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Global Proteomics Market - Key Trends & Drivers Summarized

Proteomics is the large-scale study of proteins, their structures, functions, and interactions within a biological system. As proteins are essential to nearly every cellular process, proteomics provides crucial insights into how cells function and how diseases develop. Techniques used in proteomics include mass spectrometry, protein microarrays, and various bioinformatics tools to identify and quantify proteins, analyze protein modifications, and map protein-protein interactions. These techniques allow scientists to explore the proteome, the entire set of proteins produced by an organism, tissue, or cell. By comparing proteomes under different conditions, researchers can identify disease biomarkers, understand disease mechanisms, and develop targeted therapies, making proteomics indispensable in biomedical research.

Recent advancements in proteomics have significantly enhanced its capabilities and applications. High-resolution mass spectrometry and advanced bioinformatics tools have improved the accuracy and efficiency of protein identification and quantification. Innovations such as next-generation sequencing and CRISPR technology have facilitated the integration of proteomics with genomics and transcriptomics, providing a more comprehensive understanding of cellular processes. Additionally, the development of single-cell proteomics is opening new avenues for studying cellular heterogeneity and disease progression at an unprecedented resolution. These technological advancements are driving the adoption of proteomics in various fields, including drug discovery, personalized medicine, and clinical diagnostics, as they enable more precise and detailed analysis of the proteome.

The growth in the proteomics market is driven by several factors. The increasing prevalence of chronic diseases such as cancer and cardiovascular diseases has heightened the demand for advanced diagnostic and therapeutic solutions, spurring the adoption of proteomics. The shift towards personalized medicine, which relies on understanding individual proteomic profiles to tailor treatments, is also a significant driver. Factors supporting growth also include development of protein targeted treatments and precision molecular medicines for many autoimmune diseases, development of mass spectrometry-based proteomics, and development of molecular targets in malignancies. Increasing focus of biotechnological and pharmaceutical companies in research and development for identifying new proteomics applications, development of new drugs, and proteomics biomarker discovery in different types of diseases such as cardiovascular diseases and cancer is the major trend in the global proteomics landscape. Technological advancements in mass spectrometry and bioinformatics are enhancing the capabilities of proteomic analysis, making it more accessible and cost-effective. Furthermore, the expansion of research in areas such as biomarker discovery and drug development is fueling market growth. Government and private sector investments in proteomics research and infrastructure, coupled with collaborations between academic institutions and pharmaceutical companies, are also contributing to the market's expansion. These factors, along with the growing recognition of proteomics as a critical tool in life sciences research, are propelling the growth of the proteomics market.

SCOPE OF STUDY:

The report analyzes the Proteomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Reagents, Instruments, Services); Application (Drug Discovery, Disease Diagnosis, Other Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 178 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â